The event marked the start of a long-term manufacturing agreement for a key intermediate, according to the contract development and manufacturing organization (CDMO).
The ceremony was held at Cambrex’s Karlskoga, Sweden site, at which the company recently increased capacity. As part of the expansion, which was announced in May 2017, the company installed new multi-purpose reactors ranging from 4m3 to 12m3 in addition to a 9m3 hydrogenation reactor.
The company also introduced additional continuous flow manufacturing for high purity intermediate production.
Shawn Cavanagh, COO of Cambrex, stated in a press release: “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products.”
Cavanagh said the company will continue to invest in capabilities, technology and appropriate capacity at the Karlskoga site.
Since 2012, Cambrex has invested more than $200m in facility expansions, equipment, and upgrades to the company’s global sites.